A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Machine learning models have seeped into the fabric of our lives, from curating playlists to explaining hard concepts in a ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...

This first-in-human trial is testing a highly unconventional method: delivering fat-derived stem cells from the patient ...

Scientists at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, have found that gene editing using ...

Immatics’ cell therapy has been linked to a 56% objective response rate (ORR) among 32 heavily pretreated patients with ...

Discover how Bayer and BlueRock are redefining biotech partnerships. From breakthrough Parkinson’s therapies to a unique “arm ...

Texas A&M’s Simrit Parmar partners with Saudi hospital for groundbreaking cell therapy trials targeting ALS and aplastic ...

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging field of treatments that can reprogramme immune cells inside patients ...

Alternative immune-engineering approaches, including direct in vivo immune cell engineering, are also emerging. A tumor infiltrating lymphocyte (TIL)-based therapy has recently received FDA ...